Last reviewed · How we verify

Pregabalin Release Tablets — Competitive Intelligence Brief

Pregabalin Release Tablets (Pregabalin Release Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gabapentinoid; anticonvulsant; anxiolytic. Area: Neurology; Pain Management; Psychiatry.

phase 3 Gabapentinoid; anticonvulsant; anxiolytic Voltage-gated calcium channel alpha-2-delta-1 subunit Neurology; Pain Management; Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Pregabalin Release Tablets (Pregabalin Release Tablets) — Jiangsu HengRui Medicine Co., Ltd.. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pregabalin Release Tablets TARGET Pregabalin Release Tablets Jiangsu HengRui Medicine Co., Ltd. phase 3 Gabapentinoid; anticonvulsant; anxiolytic Voltage-gated calcium channel alpha-2-delta-1 subunit
Neurontin gabapentin Generic (originally Parke-Davis/Pfizer) marketed Gabapentinoid (anticonvulsant/neuropathic pain agent) Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor 1993-12-30
Gabapentin immediate release Gabapentin immediate release Theresa Zesiewicz, MD marketed Anticonvulsant; gabapentinoid Voltage-gated calcium channel alpha-2-delta subunit
trazodone, pregabalin trazodone, pregabalin Universidad de Granada marketed Combination anxiolytic/analgesic (serotonin antagonist and reuptake inhibitor + gabapentinoid) 5-HT2A receptor, serotonin transporter (SERT), alpha-2-delta calcium channel subunit
pregabalin capsules pregabalin capsules AstraZeneca marketed Gabapentinoid; anticonvulsant; anxiolytic Alpha-2-delta-1 subunit of voltage-gated calcium channels
transdermal fentanyl matrix, gabapentin transdermal fentanyl matrix, gabapentin Seoul National University Hospital marketed Opioid analgesic + gabapentinoid Mu-opioid receptor (fentanyl); alpha-2-delta calcium channel subunit (gabapentin)
Pregabalin and dexmedetomidine Pregabalin and dexmedetomidine Wonkwang University Hospital marketed Combination analgesic/sedative (gabapentinoid + alpha-2 agonist) Alpha-2-delta calcium channel subunit (pregabalin); alpha-2 adrenergic receptor (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gabapentinoid; anticonvulsant; anxiolytic class)

  1. AstraZeneca · 1 drug in this class
  2. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
  3. Hawler Medical University · 1 drug in this class
  4. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pregabalin Release Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/pregabalin-release-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: